Skip to main content
Log in

Serum pepsinogen in screening for gastric cancer

  • Alimentary Tract
  • Published:
Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

To establish a sensitive and efficient screening method for gastric cancer using serum pepsinogen, we investigated the characteristics of serum pepsinogen I and II levels and the I/II ratio and their cut-off points. We found that the pepsinogen I level and the I/II ratio were significantly lower in patients with gastric cancer than in control subjects, especially in patients with cancers of the differentiated type, the elevated type, and the depressed type without ulceration. However, sex, depth of invasion, and location of tumor did not correlate with the pepsinogen levels. A suitable cut-off point in screening for gastric cancer was a pepsinogen I level of less than 50 ng/ml and a I/II ratio of less than 3.0, as determined by receiver operator characteristics curves. The sensitivity, the specificity, and the accuracy of detection for all types of gastric cancer were approximately 55%, 75%, and 72%, respectively. If restricted to cancers of the elevated and the depressed type without ulceration, the sensitivity was approximately 85%, and the specificity and accuracy were approximately 76% and 77%, respectively. These results suggest that, in screening for gastric cancer when using pepsinogen levels and morphological examinations, the suitable cut-off point in regard to specificity is as stated above. However, regarding sensitivity, when the pepsinogen method is used alone, a pepsinogen I level of less than 70 ng/ml and a I/II ratio of less than 3.0 is acceptable.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Chamberlain J, Day NE, Hakama M, et al. UICC workshop of the project on evaluation of screening programs for gastrointestinal cancer. Int J Cancer 1986;37:329–334.

    CAS  PubMed  Google Scholar 

  2. Hamahata M, Kusano K, Sibuye T, et al. The close examination methods and accuracy of gastric mass survey (in Japanese). Jpn J Gastroenterol Mass Survey 1993;31:3–8.

    Google Scholar 

  3. Yoshida Y, Tamura K, Arisue T, et al. Study on controlling method of the precision of the first screening of the gastric carcinoma mass survey (in Japanese). Jpn J Gastroenterol Mass Survey 1992;97:51–58.

    Google Scholar 

  4. Maruyama T, Noda Y, Kumamoto Y, et al. Estimation of frequency, population doses and stochastic risks in stomach mass screening examinationn in Japan (in Japanese with English abstract). Nippon Acta Radiol 1987;47:971–982.

    CAS  PubMed  Google Scholar 

  5. Iinuma T, Takeno Y. Cost-effectiveness of mass screening for stomach cancer (in Japanese). Jpn J Gastroenterol Mass Survey 1988;79:94–100.

    Google Scholar 

  6. Watanabe C, Sumii K, Haruma K, et al. An evaluation of gastric cancer mass survey using serum pepsinogen I and II test in local inhabitants (in Japanese). Jpn J Gastroenterol Mass Survey 1990;89:92–97.

    Google Scholar 

  7. Watanabe C, A clinical study on gastric mass assessment using serum pepsinogen I and II in a local population survey (in Japanese). Jpn J Gastroenterol Mass Survey 1992;97:42–50.

    Google Scholar 

  8. Correa P: The gastric precancerous process. Cancer Surveys 1983;2:438–450.

    Google Scholar 

  9. Jaskiewicz K, Louwrens HD. Chronic atrophic gastritis in a population at risk for gastric carcinoma. Anticancer Res 1991; 11:835–840.

    CAS  PubMed  Google Scholar 

  10. Kato I, Tominaga S, Ito Y, et al. Atrophic gastritis and stomach cancer risk; cross-sectional analyses. Jpn J Cancer Res 1992; 83:1041–1046.

    CAS  PubMed  Google Scholar 

  11. Japanese Research Society for Gastric Cancer. The general rules for gastric cancer (in Japanese). 12th ed. Tokyo: Kanehara Publications, 1993;4:18

    Google Scholar 

  12. Ichinose M, Miki K, Furihata C, et al. Radioimmunoassay of serum group I and group II pepsinogens in normal control subjects and patients with various disorders. Clin Chim Acta 1982;126:183–191.

    Article  CAS  PubMed  Google Scholar 

  13. Stemmermann GN, Samloff IM, Nomura AMY, et al. Serum pepsinogens I and II and stomach cancer. Clin Chim Acta 1987;163:191–198.

    Article  CAS  PubMed  Google Scholar 

  14. Miki K, Ichinose M, Yahagi N, et al. Mass screening for gastric cancer with serum pepsinogen test in human dry dock (stomach dry dock) (in Japanese). The Japanese Society of Human Dry Dock 1993;8:16–20.

    Google Scholar 

  15. Miki K, Ichinose M, Ishikawa K, et al. Clinical application of serum pepsinogen I and II levels for mass screening to detect gastric cancer. Jpn J Cancer Res 1993;84:1086–1090.

    CAS  PubMed  Google Scholar 

  16. Watanabe C, Haruma K, Sumii K, et al. Serum levels of pepsinogen I and gastrin, and gastric acid secretion in patients with gastric cancer (in Japanese with English abstract). Gastroenterol Endosc. 1992;34:31–38.

    Google Scholar 

  17. Kodoi A, Yoshihara M, Sumii K, et al. An evaluation of screening asymptomatic gastric cancer using serum pepsinogen I and II (in Japanese). Jpn J Gastroenterol Mass Survey 1994; 32:21–27.

    Google Scholar 

  18. Yoshihara M, Sumii K, Haruma K, et al. Evaluation of gastric mass survey using serum pepsinogen: Comparison with gastric mass screening using photofluorography (in Japanese). Jpn J Gastroenterol Mass Survey 1994;32:15–20.

    Google Scholar 

  19. Fukao A, Hishamichi S, Ohsato N, et al. Correlation between the prevalence of gastritis and gastric cancer in Japan. Cancer-Causes-Control 1993;4:17–20.

    CAS  PubMed  Google Scholar 

  20. Yoshihara M, Sumii K, Haruma K, et al. Evaluation of gastric mass survey using serum pepsinogen in a local area for 3 years (in Japanese). Jpn J Gastroenterol Mass Survey 1993;31:24–29.

    Google Scholar 

  21. Saito T. Studies on pepsinogen production in advanced gastric cancer tissue (in Japanese with English abstract). J Jpn Surg Soc 1989;90:1205–1212.

    CAS  Google Scholar 

  22. Huang SC, Miki K, Sano J, et al. Pepsinogens I and II in gastric cancer; an immunohistochemical study using monoclonal antibody. Jpn J Cancer Res (Gann) 1988;79:1139–1146.

    CAS  Google Scholar 

  23. Kodoi A, Haruma K, Yoshihara M, et al. A clinical study of pepsinogen I and II producing gastric carcinomas (in Japanese with English abstract). Jpn J Gastroenterol 1993;90:2971–2978.

    CAS  Google Scholar 

  24. Samloff IM: Cellular localization of group I pepsinogens in human gastric mucosa by immunofluorescence. Gastroenterology 1971;61:185–188.

    CAS  PubMed  Google Scholar 

  25. Asaki S, Sato H, Sato A, et al. Cancer cases detected by mass survey in aged persons. Some considerations on treatment by operation or endoscopic surgery (in Japanese). Jpn J Gastroenterol Mass Survey 1989;84:78.

    Google Scholar 

  26. Ikeda S, Yamaguti Y, Tebayasi A, et al. Analysis of the cases checked pseudo-findings with indirect flouroradiography, in gastric mass survey (in Japanese). Jpn J Gastroenterol Mass Survey 1988;78:22–28.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kodoi, A., Yoshihara, M., Sumii, K. et al. Serum pepsinogen in screening for gastric cancer. J Gastroenterol 30, 452–460 (1995). https://doi.org/10.1007/BF02347560

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02347560

Key words

Navigation